Emerging treatment options in the management of non-small cell lung cancer

Código QR

Emerging treatment options in the management of non-small cell lung cancer

Pier Luigi Filosso1, Alberto Sandri1, Alberto Oliaro1, Andrea Riccardo Filippi2, Maria Carla Cassinis3, Umberto Ricardi2, Paolo Olivo Lausi1, Sofia Asioli4, Enrico Ruffini11Department of Thoracic Surgery, 2Department of Medical and Surgical Disciplines, Radiation Therapy Division, 3Department of Med...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Filosso PL, Sandri A, Oliaro A, Filippi AR, Cassinis MC, Ricardi U, Lausi P, Asioli S, Ruffini E
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/8cfa451c17894b90843c1be84148d690
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer
por: Weise AM, et al.
Publicado: (2014)

Afatinib treatment in advanced non-small cell lung cancer
por: Hurwitz JL, et al.
Publicado: (2011)

Non-small cell lung cancer: the era of targeted therapy
por: Antonoff MB, et al.
Publicado: (2012)

Epiregulin as a therapeutic target in non-small-cell lung cancer
por: Sunaga N, et al.
Publicado: (2015)

Non-small-cell lung carcinoma: role of the Notch signaling pathway
por: Barse L, et al.
Publicado: (2015)

Emerging treatments in lung cancer – targeting the RLIP76 molecular transporter
por: Goldfinger LE, et al.
Publicado: (2013)

Breast reconstruction: current and future options
por: Paul Jr H, et al.
Publicado: (2011)

Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin
por: Kauffmann-Guerrero D, et al.
Publicado: (2020)

Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer
por: Stasi I, et al.
Publicado: (2014)

Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer
por: Burns MW, et al.
Publicado: (2015)

Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer
por: Berghmans T, et al.
Publicado: (2012)

First-line treatment of advanced ALK-positive non-small-cell lung cancer
por: Gandhi S, et al.
Publicado: (2015)

Pemetrexed in maintenance treatment of advanced non-squamous non-small-cell lung cancer
por: Minami S, et al.
Publicado: (2015)

The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer
por: Barbara Melosky, et al.
Publicado: (2021)

Aberrant Alteration of Circulating Lymphocyte Subsets in Small Cell Lung Cancer Patients Treated with Radiotherapy
por: Hui Li MD, et al.
Publicado: (2021)

Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China
por: Gou LY, Wu YL
Publicado: (2014)

Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients
por: Mehta A, et al.
Publicado: (2020)

Combination chemotherapy of gemcitabine and vinorelbine for pretreated non-small- cell lung cancer: a retrospective study
por: Minami S, et al.
Publicado: (2015)

Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence
por: Rothschild SI
Publicado: (2014)

Clinical characteristics and outcomes of Chinese patients with KRAS‐mutant non‐small cell lung cancer after chemotherapy
por: Yawen Zheng, et al.
Publicado: (2021)

Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics
por: Karachaliou N, et al.
Publicado: (2014)

Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer
por: Takeda M, et al.
Publicado: (2011)

Robotic stereotactic body radiation therapy for elderly medically inoperable early-stage non-small cell lung cancer
por: Karam SD, et al.
Publicado: (2013)

Identification and Integrate Analysis of Key Biomarkers for Diagnosis and Prognosis of Non-Small Cell Lung Cancer Based on Bioinformatics Analysis
por: Ke Gong MBBS, et al.
Publicado: (2021)

Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients
por: Chan VTC, et al.
Publicado: (2011)

Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
por: Marianne Oulhen, et al.
Publicado: (2021)

Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development
por: Ke Cheng, et al.
Publicado: (2021)

Correction: Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations
Publicado: (2021)

Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes
por: Gabriela Palma, et al.
Publicado: (2021)

Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer
por: Wallace Akerley, et al.
Publicado: (2021)

Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial
por: Fengtan Li, et al.
Publicado: (2021)

A pilot study of a metronomic chemotherapy regimen with weekly low-dose docetaxel for previously treated non-small cell lung cancer
por: Yokoi T, et al.
Publicado: (2012)

Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer
por: Mark A. Socinski, et al.
Publicado: (2021)

Prognostic Significance of TLR2, SMAD3 and Localization-dependent SATB1 in Stage I and II Non–Small-Cell Lung Cancer Patients
por: Justyna Durślewicz MSc, et al.
Publicado: (2021)

Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer
por: Chuan HUANG, et al.
Publicado: (2021)

Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis
por: Fragoulakis VF, et al.
Publicado: (2012)

Lung cancer in women
por: Barrera-Rodriguez R, et al.
Publicado: (2012)

Hepatoid Adenocarcinoma of the Lung
por: Meihui Li, et al.
Publicado: (2021)

Emerging role of brain metastases in the prognosis of breast cancer patients
por: Hambrecht A, et al.
Publicado: (2011)

Malignant retroperitoneal fibrosis in lung adenocarcinoma
por: Natalie Uy, et al.
Publicado: (2021)